Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for hospitalized depressed patients with suicidal risk
ChiCTR2300070186Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by West China Hospital of Sichuan University. Primary endpoints: COLUMBIA-SUICIDE SEVERITY RATING SCALE and Montgomery-Asberg Depression Rating Scale. Started Jan 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300070186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070186.